Ivabradine to Improve Endothelial Function in Patients With Coronary Artery Disease
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
This study evaluates the effect of ivabradine on endothelial function in patients with
coronary artery disease (CAD) after complete revascularization with percutaneous coronary
angioplasty (PCI). At least 30 days after PCI, patients will be randomized to receive
ivabradine 5 mg twice daily or to continue with standard medical therapy.